Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15612707 | 0.87 | HPGD (0.33) | ARMAPTALDH1A1 | |
| Hydrochloric Acid SCHEMBL16390253 | 0.85 | HPGD (0.36) | MAPTALDH1A1 | |
| Hydrochloric Acid SCHEMBL3698487 | 0.83 | ALDH1A1 (0.39) | ARMAPTTP53ALDH1A1 | |
| Hydrochloric Acid SCHEMBL16085943 | 0.83 | MAPT (0.32) | MAPTTP53 | |
| SCHEMBL29843859 | 0.81 | MAPT (0.33) | ARMAPTTP53IDO1TDO2 | |
| SCHEMBL17006054 | 0.81 | MAPT (0.33) | ARMAPTTP53IDO1TDO2 | |
| Hydrochloric Acid SCHEMBL3703683 | 0.80 | MAPT (0.33) | ARMAPTTP53IDO1TDO2 | |
| Hydrochloric Acid SCHEMBL482808 | 0.79 | POLB (0.36) | MAPTALDH1A1 | |
| Hydrochloric Acid SCHEMBL16390544 | 0.79 | NPC1 (0.36) | MAPTALDH1A1 | |
| SCHEMBL29723871 | 0.79 | MAPT (0.33) | ARMAPTTP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4188379-B1 | POLYCYCLIC CAP-DEPENDENT ENDONUCLEASE INHIBITORS FOR TREATING OR PREVENTING INFLUENZA | MERCK SHARP & DOHME LLC (US) | 2026-02-25 | — | — | EP | disclosed |
| US-20250248975-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | SCHRODINGER, LLC | 2025-08-07 | — | — | US | disclosed |
| US-20240357920-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2024-10-24 | — | — | US | disclosed |
| US-12091425-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-12024529-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-11970511-B2 | Tetrahydropyran-based thiodisaccharide mimics as Galectin-3 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-04-30 | — | — | US | disclosed |
| EP-3997097-B1 | MACROCYCLIC SPIROCYCLE DERIVATIVES AS MCL-1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-03-20 | — | — | EP | disclosed |
| WO-2024054851-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USING THEREOF | SIONNA THERAPEUTICS (US) | 2024-03-14 | — | — | WO | disclosed |
| US-20240067660-A1 | MACROCYCLIC SPIROCYCLE DERIVATIVES AS MCL-1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-02-29 | — | — | US | disclosed |
| US-20240018145-A1 | POLYCYCLIC CAP-DEPENDENT ENDONUCLEASE INHIBITORS FOR TREATING OR PREVENTING INFLUENZA | MERCK SHARP & DOHME LLC (US) | 2024-01-18 | — | — | US | disclosed |
| EP-2888266-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | Bristol-Myers Squibb Company (US) | 2015-07-01 | — | — | EP | disclosed |
| US-20150051353-A1 | METHOD FOR PRODUCING RING-OPENING METATHESIS POLYMER HYDRIDE, AND RESIN COMPOSITION | ZEON CORPORATION (JP) | 2015-02-19 | — | — | US | disclosed |
| EP-2826802-A1 | METHOD FOR PRODUCING RING-OPENING METATHESIS POLYMER HYDRIDE, AND RESIN COMPOSITION | Zeon Corporation (JP) | 2015-01-21 | — | — | EP | disclosed |
| US-8906929-B2 | Inhibitors of human immunodeficiency virus replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-09 | — | — | US | disclosed |
| US-20140087136-A1 | RESIN COMPOSITION AND SEMICONDUCTOR DEVICE BOARD | ZEON CORPORATION (JP) | 2014-03-27 | — | — | US | disclosed |
| US-20140051692-A1 | Inhibitors of Human Immunodeficiency Virus Replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2014-02-20 | — | — | US | disclosed |
| WO-2014028384-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-02-20 | — | — | WO | disclosed |
| EP-2070964-B9 | PROCESS FOR PRODUCTION OF HYDROGENATED POLYMERS AND HYDROGENATED POLYMERS | KURARAY CO (JP) | 2012-10-31 | — | — | EP | disclosed |
| EP-2070964-B1 | PROCESS FOR PRODUCTION OF HYDROGENATED POLYMERS AND HYDROGENATED POLYMERS | KURARAY CO (JP) | 2012-05-16 | — | — | EP | disclosed |
| EP-2070964-A1 | PROCESS FOR PRODUCTION OF HYDROGENATED POLYMERS AND HYDROGENATED POLYMERS | Kuraray Co., Ltd. (JP) | 2009-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240357920-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD1, ICOSLG, OCIAD2 | AR 184/4885MAPT 2982/4885TP53 1636/4885 |
| US-20240067660-A1 | MACROCYCLIC SPIROCYCLE DERIVATIVES AS MCL-1 INHIBITORS | MCL1, BCL2A1, BCL2L1 | AR 2872/4885MAPT 3918/4885TP53 73/4885 |
| US-20240018145-A1 | POLYCYCLIC CAP-DEPENDENT ENDONUCLEASE INHIBITORS FOR TREATING OR PREVENTING INFLUENZA | DNASE1, RNASEH1, RNASE1 | AR 4568/4885MAPT 3484/4885TP53 597/4885 |
| US-11970511-B2 | Tetrahydropyran-based thiodisaccharide mimics as Galectin-3 inhibitors | LGALS3, LGALS1, LGALS3BP | AR 4305/4885MAPT 2480/4885TP53 1878/4885 |
| US-12024529-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL2L1, BCL9 | AR 4488/4885MAPT 3369/4885TP53 31/4885 |
| US-20250248975-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | CFTR, ABCB1, PKD1 | AR 3330/4885MAPT 4827/4885TP53 2226/4885 |
| US-20140051692-A1 | Inhibitors of Human Immunodeficiency Virus Replication | EIF2AK2, RTF2, MAVS | AR 4600/4885MAPT 2620/4885TP53 1355/4885 |
| US-12091425-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL9, BCL2L1 | AR 4462/4885MAPT 3153/4885TP53 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.